| Budget Amount *help |
¥271,050,000 (Direct Cost: ¥208,500,000、Indirect Cost: ¥62,550,000)
Fiscal Year 2014: ¥48,490,000 (Direct Cost: ¥37,300,000、Indirect Cost: ¥11,190,000)
Fiscal Year 2013: ¥50,960,000 (Direct Cost: ¥39,200,000、Indirect Cost: ¥11,760,000)
Fiscal Year 2012: ¥53,430,000 (Direct Cost: ¥41,100,000、Indirect Cost: ¥12,330,000)
Fiscal Year 2011: ¥52,910,000 (Direct Cost: ¥40,700,000、Indirect Cost: ¥12,210,000)
Fiscal Year 2010: ¥65,260,000 (Direct Cost: ¥50,200,000、Indirect Cost: ¥15,060,000)
|
|---|
| Outline of Final Research Achievements |
Integrative omics analysis was performed to explore molecular targets and biomarkers for personalized medicine in cancer. Several experimental models in vitro/ in vivo were established to uncover malignant properties including epithelial-mesenchymal transition (EMT), and invasion and/or metastasis. Bioresource infrastructure was prepared, and human bioresources have been collected and preserved to facilitate multi-omics data analysis in cancer. Consequently, novel and promising targets and biomarkers including tumor suppressor microRNAs were identified, facilitating the understanding of molecular pathogenesis of intractable cancer.
|
